>LEVP – From the rodman webcast - No one else is trying for approval for that market. <
Understood, but I do not see why the C1 inhibitor from LEVP is better suited to prophylactic use than the C1 inhibitor from Pharming.
If both LEVP and Pharming get FDA approval for treatment of acute HAE and if LEVP’s trial for prophylactic use (now in progress) is successful, it would seem that Pharming ought to be able to reproduce LEVP’s prophylactic results and split that segment of the HAE market.
Market Data 
Markets 
AI
